Related Experiment Videos
Bopindolol: long-term effects on blood pressure, renal function, plasma renin activity, and plasma aldosterone in
J Shohat1, M Modan, J B Rosenfeld
1Nephrology Unit, Beilinson Medical Center, Petah Tikva, Israel.
Insights
Bopindolol effectively lowered diastolic blood pressure in hypertensive patients within four weeks. Kidney function markers remained stable, indicating a favorable safety profile for this antihypertensive medication.
Area of Science:
- Pharmacology
- Nephrology
- Cardiology
Background:
- Hypertension is a significant global health concern requiring effective pharmacologic management.
- Beta-blockers are a cornerstone in antihypertensive therapy, but their renal effects require careful consideration.
Purpose of the Study:
- To evaluate the efficacy and renal safety of bopindolol in patients with hypertension.
- To determine the optimal single daily dosage of bopindolol for blood pressure control.
Main Methods:
- A single daily dose of bopindolol (1-4 mg) was administered to hypertensive patients.
- Diastolic blood pressure was monitored over four weeks.
- Renal function was assessed by measuring inulin clearance, PAH clearance, creatinine clearance, blood urea nitrogen, and serum creatinine.
Main Results:
- 86.7% of patients achieved a diastolic blood pressure reduction of at least 10 mmHg or below 90 mmHg within four weeks.
- Inulin clearance showed a 10% decrease.
- PAH clearance, creatinine clearance, blood urea nitrogen, and serum creatinine levels remained unchanged.
Conclusions:
- Bopindolol demonstrates significant efficacy in reducing diastolic blood pressure in hypertensive patients.
- The observed decrease in inulin clearance suggests a potential mild impact on glomerular filtration, while other key renal function markers remained stable.
- Bopindolol appears to be a safe and effective antihypertensive agent with a generally well-tolerated renal safety profile.
Abstract:
Bopindolol was given to hypertensive patients in a single daily dose ranging from 1 to 4 mg. In 86.7% of the patients diastolic blood pressure was reduced by 10 mmHg or more, or lowered to below 90 mmHg, already during the first 4 wk of treatment. Inulin clearance decreased by 10%; PAH and creatinine clearance, blood urea nitrogen, and serum creatinine were unchanged.